- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00035958
Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis
Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The mortality of JDMS is 3-39% with over 40% of patients demonstrating long-term disability. Current first line therapy is high-dose corticosteroids with the attendant significant drug-related toxicity. Over 30% of JDMS patients fail to respond adequately to steroids and require additional immunosuppression, none of which have been tested in prospective, randomized, controlled trials. The unique occlusive vasculopathy in JDMS is critical in the pathogenesis and predictive of prognosis but poorly understood. Elevated levels of tumor necrosis factor (TNF) alpha have been shown to be present in JDMS and are associated with a more severe and chronic course.
Seventy-five children with definite JDMS will be enrolled in a 24-month prospective, randomized, multicentered trial comparing 3 treatments: oral prednisone (P), combination of oral prednisone and methotrexate (P/MTX), and combination of oral prednisone and etanercept (P/E). Primary response measures will be muscle strength and mean duration of steroid therapy. Secondary response variables are disability in daily function and height and weight growth velocity (steroid toxicity measures). The combination of P/E will be tested and compared to both P alone and the combination of P/MTX after 3, 6, 12, 18, and 24 months of treatment. In addition, the combination of P/MTX will be compared to P alone after 3, 6, 12, 18, and 24 months of treatment. In pretreatment muscle biopsies, proangiogenic factors (such as vascular endothelial cell growth factor and basic fibroblast growth factor), angiostatic factors (such as angiostatin and endostatin), and vascular morphology (vessel number, width, length and area) will be quantified and tested for ability to predict muscle strength and functional ability 3, 6, 12, 18, and 24 months later.
Study Type
Enrollment
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Childrens Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria at the time of enrollment:
- Definite or probable diagnosis of JDMS by the criteria of Bohan and Peter
- No prior systemic steroid treatment for JDMS
- If able to become pregnant (females) or impregnate (males) and are sexually active, then must have negative serum pregnancy test at baseline and be utilizing effective form of birth control
- Patient and/or parent or legal guardian must be willing to sign consent and assent forms
Exclusion criteria at the time of enrollment:
- History of chronic or recurrent infections sufficient to preclude the use of etanercept
- Prior treatment with specific TNF-blocking agents
- Demonstration of cutaneous or gastrointestinal (GI) ulceration at the time of diagnosis
- JDMS-related pulmonary disease at time of diagnosis (interstitial lung disease or aspiration pneumonia confirmed by radiograph)
- JDMS-related cardiomyopathy (echocardiogram confirmation)
- Any uncontrolled, clinically significant pre-existent systemic disease (hepatic, renal, neurological, endocrine, cardiac, gastrointestinal, or hematologic disease) within 24 weeks of start of study
- Known HIV, hepatitis B surface antigen not related to vaccination, or hepatitis C antibody positivity
- Pregnant or nursing female
- Any of the following laboratory abnormalities at baseline: platelet count < 100,000/cmm, total white cell count of < 3000 cells/cmm, neutrophils < 1000 cells/cmm, serum bilirubin > 2 times upper limit of normal, estimated creatinine clearance of < 90 mL/min/1.73 M2 BSA estimated by formula for males age 2 to <13 (0.55 X ht in cms/serum creatinine), age 13-18 (0.7 X ht in cms/serum creatinine) and females age 2-18 (0.55 X ht in cms/serum creatinine)
- Received live virus vaccination within 3 months prior to study entry (contraindication for MTX or etanercept therapy)
- Past or current substance abuse or psychiatric history that would interfere with ability to give informed consent or comply with study requirements or physician instructions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Daniel J. Lovell, MD, MPH, Children's Hospital Medical Center, Cincinnati
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Skin Diseases
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Polymyositis
- Myositis
- Dermatomyositis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Etanercept
- Prednisone
- Methotrexate
Other Study ID Numbers
- P60AR047784 (U.S. NIH Grant/Contract)
- NIAMS-078
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatomyositis
-
Istituto Giannina GasliniPediatric Rheumatology International Trials OrganizationCompletedJuvenile DermatomyositisItaly
-
The First Hospital of Jilin UniversityCompletedJuvenile Dermatomyositis
-
The Cleveland ClinicMallinckrodtCompletedDermatomyositis | Juvenile DermatomyositisUnited States
-
Biotech Pharmaceutical Co., Ltd.Not yet recruitingDermatomyositis, Adult Type
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingDermatomyositis, Adult TypeChina
-
Tulane UniversityCompletedDermatomyositis, Adult TypeUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingJuvenile DermatomyositisFrance
-
The Hospital for Sick ChildrenCompletedJuvenile DermatomyositisCanada
-
Second Affiliated Hospital, School of Medicine,...RecruitingGastric Mucosal Manifestations in Patients With DermatomyositisChina
-
MedImmune LLCCompletedDERMATOMYOSITIS OR POLYMYOSITISUnited States
Clinical Trials on Etanercept
-
EMSWithdrawnRheumatoid ArthritisBrazil
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAnkylosing Spondylitis
-
LG Life SciencesCompletedHealthyKorea, Republic of
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...CompletedAnkylosing SpondylitisChina
-
Shanghai Celgen Bio-Pharmaceutical Co.,LtdUnknownPsoriasis | Plaque PsoriasisChina
-
Sun Yat-sen UniversityCompleted
-
AmgenCompletedArthritis, Rheumatoid; Arthritis, PsoriaticUnited States, Puerto Rico
-
AmgenCompletedRheumatoid Arthritis | Plaque PsoriasisUnited States, Canada
-
Samsung Bioepis Co., Ltd.CompletedRheumatoid ArthritisPoland, United Kingdom